By Sam Baker - 06/18/12 03:21 PM EDT
The Supreme Court’s majority rejected that interpretation, in part because the Labor Department only adopted it in this case. The department had not tried to write its definition of “sales” into regulations, so the public never had a chance to weigh in, and it had never taken action against drug companies for not paying overtime.
“The DOL’s current interpretation — that a sale demands a transfer of title — is quite unpersuasive,” Justice Samuel Alito said in the majority opinion. “It plainly lacks the hallmarks of thorough consideration.”
Also in the majority were Chief Justice John Roberts and Justices Antonin Scalia, Clarence Thomas and Anthony Kennedy — the four conservative members and Kennedy, the court’s traditional swing vote.
Justices Stephen Breyer, Sonia Sotomayor, Elena Kagan and Ruth Bader Ginsburg dissented.
Pharmaceutical representatives — known in industry jargon as “detailers” — do not directly sell a product and therefore are not salespeople, Breyer wrote in the dissenting opinion.
“What the detailer does is inform the doctor about the nature of the manufacturer’s drugs and explain their uses, their virtues, their drawbacks, and their limitations,” Breyer wrote. “The detailer may well try to convince the doctor to prescribe the manufacturer’s drugs for patients … Where in this process does” the detailer sell the product?”